Zomedica Corp. 8K

Zomedica announced record Q1 2026 revenue of $8.8 million with improved margins, reduced expenses and cash burn, and $47.5 million in liquidity, while still generating a net and Adjusted EBITDA loss.

Zomedica Corp. reported record first quarter 2026 revenue of $8.8 million, up 35% year over year and marking its 21st consecutive quarter of record year-over-year revenue, driven by strong performance in its PulseVet and Assisi therapeutic devices, increased adoption of its TRUFORMA diagnostics platform, and contributions from its new Development Services segment, while maintaining a 62% gross margin, reducing operating expenses (excluding prior-year impairments) by 21% to $10.4 million, cutting quarterly cash burn by 15% to $5.7 million, and ending the quarter with $47.5 million in liquidity and 979.9 million shares outstanding, despite posting a net loss of $4.5 million and a Non-GAAP Adjusted EBITDA loss of $2.4 million.

Filing Facts

CIK

1684144

Ticker

-

Form

8K

Source Type

sec

Accession

0001654954-26-004419

Alert Tier

6